Arcutis Biotherapeutics Inc. (ARQT) 12-Month Stock Forecast & Price Target Cone
Arcutis Biotherapeutics Inc. (ARQT) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Drag to Test Your ARQT Position Size: $10,000
Wall Street Analyst Breakdown & Historical Accuracy Audit (28 Desks)
Street Historical Accuracy: 64/100| Wall Street Firm | Stance | 12M Target | 1Y Accuracy | Track Grade |
|---|---|---|---|---|
| Morgan StanleyInstitutional Equity Desk | HOLD | $34 | 74% | A |
| Goldman SachsSector Coverage Lead | BUY | $36 | 69% | B |
| JP MorganUS Large-Cap Research | HOLD | $29 | 58% | C |
Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live ARQT Tape Review)
- ✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
- ✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
- ✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen
ARQT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +91.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ARQT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ARQT. Explore sector supply chains on /butterfly.
ARQT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhat is ARQT's 12-month stock price target?
Arcutis Biotherapeutics Inc. (ARQT) carries a 12-month consensus base price target of $32.69 (+2.3% from $31.97), with a bull-case target of $38.57 and a bear-case floor of $25.5.
Is ARQT stock a Buy, Hold, or Sell right now?
Roarable's 5-Pillar RQD Quant Engine rates ARQT C (Hold — HOLD) with an RQD Confidence score of 63/100.